Omega Diagnostics Gp (ODX.L) Update on CTDA Regulations

Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Global Health (CD4 and COVID-19) and Health and Nutrition products, notes the UK Health Security Agency’s Medical Devices (Coronavirus Test Device Approvals) (Amendment) Regulations 2021 (“CTDA”) which were implemented on 1 November 2021.

The new CTDA Regulations required all suppliers of COVID-19 tests to submit information regarding their products for desktop review prior to 31 October 2021 if they wished their products to remain on sale in the UK after this date. This is a new requirement over and above the requirement for the CE Mark secured for Omega’s VISITECT® professional-use COVID-19 Antigen test (“LFT”) earlier this year.

Omega submitted all documentation ahead of the published deadlines and paid the necessary fee, however, in line with the vast majority of available tests on the market Omega’s existing LFT has yet to be approved under CTDA.

This new legislation is not expected to cause a delay in the supply of Omega’s VISITECT® professional-use COVID-19 Antigen test to DAM Health clinics in the UK under the agreement announced on 1 November 2021. Omega currently remains free to supply LFTs to DAM Health’s clinics throughout Europe and DAM Health are able to distribute Omega’s LFT throughout Europe

The Company will update shareholders as soon as they receive a further update from the UK Health Security Agency.

Contacts:

Omega Diagnostics Group PLC

www.omegadx.com

Colin King, Chief Executive

via Walbrook PR

Chris Lea, Chief Financial Officer

About Omega Diagnostics Group PLC

Omega manufactures and distributes high quality in-vitro diagnostic products for use in hospitals, clinics, laboratories and healthcare practitioners in over 75 countries and specialise in the areas of health and nutrition and global health.


Linking Shareholders and Executives :Share Talk

If anyone reads this article found it useful, helpful? Then please subscribe www.share-talk.com or follow SHARE TALK on our Twitter page for future updates. Terms of Website Use All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned

Subscribe To Our Daily Update

Share via
Copy link
Malcare WordPress Security